InMed Pharmaceuticals Inc. · NASDAQ:INM
InMed Pharmaceuticals — Canaccord Genuity Growth Conference 2018
27 slides from InMed Pharmaceuticals's conference presentation, Aug 8, 2018
Slide 1: Unlocking the Potential of Cannabinoid Medicines
UNLOCKING THE POTENTIAL OF CANNABINOID MEDICINES I N V E S T O R P R E S E N TAT I O N August 8, 2018 www.inmedpharma.com :IN :IMLFF
Slide 2: Disclaimers
DISCLAIMERS UNLOCKING CANNABINOID MEDICINES This presentation does not constitute an offering of securities and the information contained herein is subject to the information contained in the Company’s continuous disclosure documents on SEDAR at www.sedar.com. Information concerning the assets and o
Slide 3: Disclaimers: Forward Looking Statements
DISCLAIMERS UNLOCKING CANNABINOID MEDICINES FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) including statements concerning anticipated clini
Slide 4: InMed's Unique Approach
INMED’S UNIQUE APPROACH UNLOCKING CANNABINOID MEDICINES InMed explores the potential of all 90+ cannabinoid compounds, NOT just THC & CBD InMed selects specific cannabinoids (or combinations thereof) that have potential to play a role in regulating specific diseases InMed biosynthesizes cannabinoids
Slide 5: The Plant and Its Relation to Humans
THE PLANT AND ITS RELATION TO HUMANS UNLOCKING CANNABINOID MEDICINE e The human body has a natural, extensive ‘endocannabinoid’ receptor system located in the mammalian brain, throughout the central and peripheral nervous The cannabis plant systems, and in tissues naturally produces and organs. This
Slide 6: The Medicinal Role of Cannabinoids
THE MEDICINAL ROLE OF CANNABINOIDS … UNLOCKING CANNABINOID MEDICINES … is rapidly evolving in many diseases, albeit with only 2 specific drugs Tetrahydrocannabinol Cannabidiol (THC) (CBD) • Pain • Epilepsy • Nausea • Anxiety • Stress Disorder • Stress Disorder • Sleep Apnea • Inflammation THC and CB
Slide 7: The Components of Cannabis
THE COMPONENTS OF CANNABIS UNLOCKING CANNABINOID MEDICINES Despite the medical potential of these 90+ other cannabinoids, their role in treating disease remains largely unexplored because: They occur in extremely low concentrations in the cannabis plant. The cost of isolating sufficient quantities t
Slide 8: Methods of Cannabinoid Manufacturing
METHODS OF CANNABINOID MANUFACTURING UNLOCKING CANNABINOID MEDICINES Extraction From Plants B Chemical Synthesis • Plant - Grow - Harvest - Extract - I • Expensive, time consuming Purify process is massively O (weeks) resource intensive, large carbon S • Excessive (toxic) waste footprint, QA/QC issu
Slide 9: What Is Biosynthesis?
WHAT IS BIOSYNTHESIS? UNLOCKING CANNABINOID MEDICINES High Level View … Biosynthesis is a way to mimic what naturally happens in the plant: a multi-step, enzyme-catalyzed process where components are converted into more complex products inside living organisms. Performed using the same starting mate
Slide 10: How Does the Cannabis Plant Make Drugs?
HOW DOES THE CANNABIS PLANT MAKE DRUGS? UNLOCKING CANNABINOID MEDICINES Precursor assembly Gateway Diversification © InMed Pharmaceuticals Inc. and University of British Columbia 10 Investor Presentation • August 8, 2018 • InMed Pharmaceuticals
Slide 11: Benefits of Biosynthesis
BENEFITS OF BIOSYNTHESIS UNLOCKING CANNABINOID MEDICINES The benefits of InMed’s biosynthesis manufacturing technology: Significant cost and time savings vs. existing growing / harvesting / 1 extraction / purification methods Access to minor cannabinoids that are currently economically unfeasible 2
Slide 12: Biosynthesis: Revenue Opportunities
BIOSYNTHESIS: REVENUE OPPORTUNITIES UNLOCKING CANNABINOID MEDICINE Three distinct revenue opportunities from biosynthesis: 1. Supplier of drug product to the pharmaceutical industry: • Global annual sales of Epidiolex® are expected to peak at ~$2.2B a • Continued approvals in this space will grow th
Slide 13: Meet Our Biosynthesis Team
MEET OUR BIOSYNTHESIS TEAM UNLOCKING CANNABINOID MEDICINES Dr. Eric Hsu, VP of Preclinical R&D, InMed: Extensive experience in novel gene transfer technologies and manufacturing process development, CMC and coordinating partnership activities Dr. Vikram Yadav, Associate Professor, Department of Chem
Slide 14: Significant Clinical Opportunities
SIGNIFICANT CLINICAL OPPORTUNITES UNLOCKING CANNABINOID MEDICINES Of the extensive spectrum of potential diseases, InMed’s initial two target indications address total market opportunities of > $6.6B 14 Investor Presentation • August 8, 2018 • InMed Pharmaceuticals
Slide 15: Our R&D Pipeline
OUR R&D PIPELINE UNLOCKING CANNABINOID MEDICINES INM-750 INM-085 INM-405 Epidermolysis Glaucoma Pain bullosa Program Therapeutic Area A rare skin disease with A serious eye disease Targeting peripheral no approved leading to blindness pain such as joint and treatments muscle disorders 50,000a 91 mil
Slide 16: INM-750 for the Treatment of Epidermolysis Bullosa
INM-750 FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA UNLOCKING CANNABINOID MEDICINES “The Worst Disease You’ve Never Heard Of” • Epidermolysis bullosa (EB) Epidermis is a group of genetic EBS Skin Sample conditions that cause the skin to be very fragile and to blister / rupture easily in response to m
Slide 17: INM-750 for the Treatment of Epidermolysis Bullosa
INM-750 FOR THE TREATMENT OF EPIDERMOLYSIS BULLOSA UNLOCKING CANNABINOID MEDICINES • INM-750 is being investigated to deliver symptomatic relief in all EB patients via multiple potential mechanisms of action: • accelerated wound healing • pain reduction • itch reduction • reduce inflammation • antim
Slide 18: INM-085 for the Treatment of Glaucoma
INM-085 FOR THE TREATMENT OF GLAUCOMA UNLOCKING CANNABINOID MEDICINES Proprietary Delivery System Dual Mechanism of Action ü INM-085 utilizes a 1x per day ü Reduces the intraocular pressure hydrogel to improve compliance (IOP) in the affected eyes ü Preclinical animal data showed ü Provide neuroprot
Slide 19: INM-085 for the Treatment of Glaucoma
INM-085 FOR THE TREATMENT OF GLAUCOMA UNLOCKING CANNABINOID MEDICINES INM-085 Increases Blood Vessel Diameter in Pre-clinical Mouse Model Ø Optical Coherence Tomography scan of a mouse retina (left untreated & right treated) showed an increase of blood vessel diameter after 30 min of application. Ø
Slide 20: INM-405 for the Treatment of Pain
INM-405 FOR THE TREATMENT OF PAIN UNLOCKING CANNABINOID MEDICINES Local (topical) administration for Peripheral Pain Management Temporomandibular Disorders (TMD) q Musculoskeletal and Neuromuscular q TMJ, muscles and tissues q Mild to severe; 2x more women than men q 5-12% of total population q Trea
Slide 21: Development Targets
DEVELOPMENT TARGETS UNLOCKING CANNABINOID MEDICINES Biosynthesis 3Q18: Engage CMO for bio-fermentation process optimization and scale up 3Q18: Engage CMO for purification process development and scale up 1H19: Finalize fermentation and purification process development and scale up INM-750 for EB INM
Slide 22: Executive Team: Business & Finance
EXECUTIVE TEAM: BUSINESS & FINANCE UNLOCKING CANNABINOID MEDICINES Eric A. Adams Jeff Charpentier Josh Blacher President & CEO Chief Financial Officer Chief Business Officer 25+ years experience in 25+ years experience in 20+ years of senior global biopharma biotech and tech leadership, capital lead
Slide 23: Executive Team: Science
EXECUTIVE TEAM: SCIENCE UNLOCKING CANNABINOID MEDICINES Sazzad Hossain, Ph.D. Alexandra Mancini, M.Sc. Eric Hsu, Ph.D. Chief Scientific Officer SVP, Clinical and Regulatory VP, Preclinical R&D 20+ years of Affairs 18+ years of scientific academic/industry 30+ years’ global leadership experience expe
Slide 24: Board of Directors
BOARD OF DIRECTORS UNLOCKING CANNABINOID MEDICINES William Garner, MD Chairman Founder of EGB Ventures LLC Chairman/Founder of Race Oncology(ASX:RAC); Formerly Director +/- Executive at IGXBio; Invion Limited (ASX:IVX); Del Mar Pharma (NASDAQ: DMPI); Hoffmann LaRoche and healthcare merchant banking
Slide 25: Financial Snapshot
FINANCIAL SNAPSHOT UNLOCKING CANNABINOID MEDICINES Cash equivalents and short-term investments: ~$23 million at March 31, 2018 (includes C$15.0 million gross proceeds raised in June, 2018) Shares I/O: 170.9 M Options/Warrants: 50.5 M Diluted Shares: 221.4 M :IMLFF :IN* Previous close (2018-08-02): $
Slide 26: InMed at a Glance
INMED AT A GLANCE UNLOCKING CANNABINOID MEDICINES We’re building a technologically advanced cannabinoid pharmaceutical company unlike any others… Robust, innovative and disruptive biosynthesis manufacturing technology Diverse pipeline across a spectrum of diseases with high unmet medical needs World
Slide 27: Thank You!
Thank You! Eric A. Adams Josh Blacher Chief Executive Officer Chief Business Officer eadams@inmedpharma.com jblacher@inmedpharma.com +1-604-669-7207 +1-917-880-3423 www.inmedpharma.com :IN :IMLFF
InMed Pharmaceuticals — Canaccord Genuity Growth Conference 2018 on 6ix